Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

NCT ID: NCT07031063

Last Updated: 2025-06-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 124 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-01
• Study Completion Date: 2028-12-01

Brief Summary

Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on the long-term adverse effects of antiretrovirals, especially integrase strand transfer inhibitors, as they have been associated with significant weight gain, which may be associated with increased cardiovascular risk.

Objective: To determine the effectiveness, safety, and tolerability of Dolutegravir/Lamivudine (DTG/3TC) compared with Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/TAF/FTC) in treatment-naive people living with HIV (PWH). Materials and methods: With prior approval from the Ethics and Scientific Research Committee 3502, an open-label, randomized clinical trial will be conducted at the Infectious Diseases Hospital of the National Medical Center "La Raza" from November 2024 to May 2026. Recently diagnosed PWH with no history of PrEP and/or PeP use, without hospitalization criteria, and without a diagnosis of metabolic syndrome based on ATP-III criteria will be identified. They will be invited to participate in the study and, if they accept, they will sign an informed consent form. They will be randomized to start a BIC/TAF/FTC or DTG/3TC 1:1 regimen. Laboratory studies, vital signs, and somatometry including bioimpedance will be performed at 4, 12, 24, 36, 48, 72, 96, 120, 144 weeks of follow-up; viral load and CD4+ count will be measured at weeks 12, 24, 48, 72, 96, 120, 144 weeks after the start of treatment. Sampling will be non-probabilistic; the distribution will be identified using the Kolmogorov-Smirnoff test, and measures of central tendency and percentages will be expressed. Comparisons will be made using the Mann-Whitney U test. Qualitative data will be analyzed using the x2 or Fisher's exact test. Group analysis will be performed at 12, 24, 48, 96 and 144 weeks using the Wilcoxon test. A P value ≤0.05 with a 95% confidence interval will be considered statistically significant.

Detailed Description

With prior approval of the protocol by the Local Ethics and Scientific Research Committee 3502, PWH attending the HIV clinic at the Infectious Diseases Hospital who are ART (antiretroviral therapy) naive and meet all the protocol inclusion criteria will be identified. They will be invited to participate in the study protocol, and will sign informed consent during the medical visit. If they accept, they will be explained that they can withdraw from the study whenever they wish. The initial medical interview will then be conducted to assess the sociodemographic, clinical, and comorbid characteristics of the PWH, eating habits, exercise, alcoholism and smoking; in addition, anthropometric measurements will be taken with the 4-point bioimpedance equipment (FitScan segmental body composition monitor C-545F), which expresses weight in kilograms, water in %, muscle in kg, bone in kg, fat in %; waist and hip will be recorded on the data collection sheet. The principal or associate investigator will take measurements in centimeters, in addition to vital signs such as blood pressure, heart rate, respiratory rate, oxygen saturation, prior to entering the study. In addition, in that first consultation, the following will be assessed: Glucose, creatinine, lipid profile, liver function test, complete blood count, viral load, CD4+, hepatitis B virus serology, hepatitis C virus serology, and VDRL. Randomization will be performed using the MEDSHARING digital system for each of the two arms, consisting of DTG/3TC or BIC/FTC/TAF. Follow-up appointments will be held at 4, 12, 24, 36, 48, 72, 96, 120, 144 weeks after randomization with further laboratory studies at baseline and at 4, 12, 24, 36, 48, 72, 96, 120, 144 week. Glucose, creatinine, lipid profile, liver profile, complete blood count, adverse events by organ and system, and DAIDS scale will be assessed at 4, 12, 24, 48, 72, 96, 120, 144 weeks after randomization; HIV-1 viral load and CD4+ count will be assessed at 12, 24, 48, 72, 96, 120 and 144 weeks after study entry.Also, Neuropsychiatric disorders will be assessed with scales for depression, anxiety and insomnia: Hospital Anxiety and Depression Scale (HADS-D, HADS-A), Insomnia Severity Index (ISI), Patient Health Questionnaire (PHQ-9) prior to entering the protocol, at 4, 12, 24, 48 72, 96, 120 and 144 weeks after randomization; satisfaction with the treatment and distress associated with it will be assessed using the HIVTSQ and HIVSDM scales will be measured after 4, 12, 24, 48, 72, 96, 129, 144 weeks after randomization.

Sampling and Sample Calculation Sampling will be simple random sampling (1:1), with participation in the study offered to all ART-naive PWH who meet the selection criteria and sign the informed consent form. For this study, the target sample size was 103 participants per treatment group, based on 80% power, an α level of 2.5%, a non-inferiority margin of -10% for virologic efficacy (non-inferiority is established if the lower bound of the 2-sided 95% CI for the difference in response is greater than -10% between the two groups), and an assumed true response of 93% at week 48 for both treatment groups. Considering a 20% attrition rate, a total of 124 patients (62 PWH in each arm) are planned for enrollment.

Statistical Analysis Data will be described using proportions, frequencies, or percentages for categorical variables and using mean and standard deviation or median and percentile, according to their Kolmogorov-Smirnov distribution, for quantitative variables.

The incidence rate of metabolic syndrome, significant weight gain, dyslipidemia, overweight/obesity, and dyslipidemia will be calculated.

The Chi-square test or Fisher's exact test will be used to determine the relative risk of developing metabolic changes with the factors analyzed.

In the bivariate analysis, the paired T test or Wilcoxon paired rank sum test will be used to assess statistical significance at baseline at 48 weeks of follow-up. Statistical significance will be considered as a p value ≤0.05 with a 95% CI. For measurements at baseline, 24, and 48 weeks, the Friedman test or ANOVA will be used, depending on the type of variable.

The differences between the two groups with respect to metabolic changes and the variables studied will be determined using the Student t test or the Mann-Whitney U test, as appropriate.

In the multivariate analysis, binary logistic regression will be performed on all variables that were statistically significant in the bivariate analysis to determine the independence of the variables. Statistical analysis will be performed using SPSS (IBM) version 29.0.2 for the Mac OS Ventura operating system.

This protocol will be submitted to the institution's Ethics and Scientific Research Committee for authorization in accordance with international guidelines, including the Declaration of Helsinki, the international guidelines for biomedical ETHICS This protocol will be submitted to the institution's Ethics and Scientific Research Committee for authorization in accordance with international guidelines, including the Declaration of Helsinki, the international guidelines for biomedical research involving human subjects, from the Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO), as well as the Guidelines for Good Clinical Practice of the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH).

Confidentiality of results: This protocol will be conducted in accordance with the guidelines of local hospital authorities and based on legal structures that do not overrule the Mexican Social Security Institute. All procedures will be in accordance with the provisions of the Regulations of the General Health Law on Clinical Research. Likewise, this study will comply with the Organic Law based on public statistics, which guarantees that those providing information will be included, with the exception of identifying individuals. A unique folio number will be established on the data collection sheet, where the study will be entered, and all personal data of participants will be removed.

In the Regulations of the General Health Law on Health Research, Article 17, the randomization process considers a risk greater than minimal.

The regimens that will be used in the treatment of ART-naive PWH are recommended by national and international guidelines, so candidate PWH will receive the best treatment option in Mexico.

The probability of complications corresponding to the adverse events inherent to each treatment regimen corresponds to the adverse events inherent to each treatment regimen. Furthermore, laboratory tests are usually requested for monitoring PWH who begin ART in IMSS units. Obtaining laboratory studies may be associated with adverse events related to venipuncture and the use of sterile materials, such as pain, bruising, vascular injuries, nerve injuries, or infections. If any of these occur, participants will be instructed to seek evaluation and will receive medical treatment if necessary.

Conditions

HIV Infection; Metabolic Syndrome; Antiretroviral Treatment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BIC/TAF/FTC

Bictegravir/ tenofovir alafenamide/ emtricitabine 50/ 25/ 200 mg. It is the usual therapy, consisting of 3 drugs in a single tablet, based on an integrase inhibitor, and 2 nucleoside analogues.

Group Type: ACTIVE_COMPARATOR

Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

Intervention Type: DRUG

It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.

DTG/3TC

Dolutegravir/lamivudine 50/300 mg. 2-drug therapy in 1 tablet, co-formulated with 1 integrase inhibitor and 1 nucleoside analogue

Group Type: EXPERIMENTAL

DTG/3TC

Intervention Type: DRUG

Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group

Interventions

DTG/3TC

Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group

Intervention Type: DRUG

Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.

Intervention Type: DRUG

Other Intervention Names

Dual therapy

Eligibility Criteria

Inclusion Criteria

1. Men and women ≥18 years of age , diagnosed with HIV, and naive to antiretroviral treatment.

2. HIV-1 RNA quantified by RT-PCR ≥500 and less than 500,000 copies/mL.

3. No history of PrEP or PEP use.

4. Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 SC.

5. No current or planned use of medications associated with significant weight changes during the study period.

6. Be a beneficiary of the Mexican Social Security Institute treated at the Infectious Diseases Hospital, La Raza National Medical Center.

7. Willingness of the participant to give consent.

Exclusion Criteria

1. Diagnosis of metabolic syndrome.

2. uncontrolled diabetes

3. Contraindication to the use of INSTIs.

4. Known mutations in any of the components of either regimen (second-generation INSTIs, 3TC/FTC, or TAF).

5. Co-medications that have potential interactions with any of the components of the antiretroviral regimens.

6. Coinfection with hepatitis B or hepatitis C virus.

7. High cardiovascular risk (Framinham >20% or AHA/ACC >7.5%).

8. Use of recreational drugs with anorexigenic potential (crystal, methamphetamines, cocaine) 60 days prior to randomization.

9. Hospitalization for acute or severe illness 30 days prior to randomization

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Instituto Mexicano del Seguro Social

OTHER_GOV

Sponsor Role: lead

Responsible Party

José Antonio Mata Marín

Dr. José Antonio Mata Marín

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

José A Mata, Master degree

Role: PRINCIPAL_INVESTIGATOR

Instituto Mexicano del Seguro Social

Locations

Hospital de infectología, Centro Médico Nacional La Raza

Mexico City, Azcapotzalco, Mexico

Site Status: RECRUITING

Countries

Mexico

Central Contacts

José A Mata, M.Sc.

Role: CONTACT

jamatamarin@gmail.com

525530379053

Ana L Cano, Posgraduate

Role: CONTACT

ana.knodiaz@gmail.com

522291243665

Facility Contacts

Ana Cano Díaz

Role: primary

ana.knodiaz@gmail.com

2291243665

Role: backup

ana.knodiaz@gmail.com

References

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.

Reference Type: BACKGROUND

PMID: 28867497 (View on PubMed)

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum. J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e21. doi: 10.1097/QAI.0000000000002394.

Reference Type: BACKGROUND

PMID: 32530908 (View on PubMed)

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.

Reference Type: BACKGROUND

PMID: 30420123 (View on PubMed)

Kelly SG, Nyaku AN, Taiwo BO. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? Drugs. 2016 Apr;76(5):523-31. doi: 10.1007/s40265-016-0553-8.

Reference Type: BACKGROUND

PMID: 26886135 (View on PubMed)

Other Identifiers

R-2025-3502-071

Identifier Type: -

Identifier Source: org_study_id